Takeda Pharmaceutical (TKPHF) Cash from Operations (2018 - 2026)
Takeda Pharmaceutical (TKPHF) recorded quarterly Cash from Operations of 475231517.53 in Q1 2026, down 80.41% quarter-over-quarter from 2425354411.72 in Q4 2025, and down 67.36% on a YoY basis from 1456165908.8 in Q1 2025.
Takeda Pharmaceutical (TKPHF) Cash from Operations (2018 - 2026) Analysis & Trends
Takeda Pharmaceutical's Cash from Operations history runs 9 years deep, the most recent figure standing at 475231517.53 for Q1 2026.
- In Q1 2026, Cash from Operations fell 67.36% year-over-year to 475231517.53; the TTM figure through Mar 2026 stood at 6956339437.92 (changed 0.02% YoY), while the FY2026 annual figure was 6918418458.19, changed 0.31% from the prior year.
- Cash from Operations was 475231517.53 for Q1 2026 at Takeda Pharmaceutical, down from 2425354411.72 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 3626205754.83 in Q1 2023 to a low of 475231517.53 in Q1 2026.
- Historically, Cash from Operations has averaged 1881568313.6 across 5 years, with a median of 1600108410.1 in 2022.
- The sharpest annual moves came in 2024 and 2026: Cash from Operations surged 154.78% in 2024, then tumbled 67.36% in 2026.
- A 5-year view of Cash from Operations shows it stood at 2677225361.33 in 2022, then slumped by 62.99% to 990775096.48 in 2023, then jumped by 154.78% to 2524260483.73 in 2024, then dropped by 3.92% to 2425354411.72 in 2025, then tumbled by 80.41% to 475231517.53 in 2026.
- The last three Cash from Operations figures came in at 475231517.53 (Q1 2026), 2425354411.72 (Q4 2025), and 2566942324.35 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | -40.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 401.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 463.30 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 145.80 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 13.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -165.74 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 89.36 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 125.13 Mn |
| 10 | Takeda Pharmaceutical | - | - | 4.39 Bn | 475.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 475.23 Mn |
| Mar 31, 2026 | 475.23 Mn |
| Dec 31, 2025 | 2.43 Bn |
| Dec 31, 2025 | 2.43 Bn |
| Sep 30, 2025 | 2.57 Bn |
| Sep 30, 2025 | 2.57 Bn |
| Jun 30, 2025 | 1.49 Bn |
| Jun 30, 2025 | 1.49 Bn |
| Mar 31, 2025 | 1.46 Bn |
| Mar 31, 2025 | 1.46 Bn |
| Dec 31, 2024 | 2.52 Bn |
| Dec 31, 2024 | 2.52 Bn |
| Sep 30, 2024 | 1.88 Bn |
| Sep 30, 2024 | 1.88 Bn |
| Jun 30, 2024 | 1.09 Bn |
| Jun 30, 2024 | 1.09 Bn |
| Mar 31, 2024 | 3.24 Bn |
| Mar 31, 2024 | 3.24 Bn |
| Dec 31, 2023 | 990.78 Mn |
| Dec 31, 2023 | 990.78 Mn |